AM 1030: A Phase I/II, Double-Blind, Placebo-Controlled, Single and Multiple Ascending (Topical) Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Patients (Male and Female) with Atopic Dermatitis
Phase of Trial: Phase I/II
Latest Information Update: 16 Dec 2015
Price : $35 *
At a glance
- Drugs AM 1030 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors AnaMar AB
- 11 Aug 2015 According to an AnaMar media release, headline data from this trial is expected to be released in September 2015.
- 11 Aug 2015 Status changed from recruiting to completed, according to an AnaMar media release.
- 12 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov